The Earlier, the Better

Article metrics

References

  1. 1

    Ikeda N, Hasegawa T, Hasegawa T, Saito I, Saruta T : Awareness of the Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2000) and compliance to its recommendations: surveys in 2000 and 2004. J Hum Hypertens 2006; 20: 263–266.

  2. 2

    Nagai Y, Yao L, Kobori H, et al: Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol 2005; 16: 703–711.

  3. 3

    Hilgers KF, Veelken R : Type 2 diabetic nephropathy: never too early to treat? J Am Soc Nephrol 2005; 16: 574–575.

  4. 4

    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–2997.

  5. 5

    Dahlof B, Devereux RB, Kjeldsen SE, et al, LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.

  6. 6

    Pfeffer MA, Swedberg K, Granger CB, et al, CHARM Investigators and Committees : Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759–766.

  7. 7

    Julius S, Nesbitt SD, Egan BM, et al, Trial of Preventing Hypertension (TROPHY) Study Investigators : Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354: 1685–1697.

  8. 8

    Nakaya H, Sasamura H, Hayashi M, Saruta T : Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis. J Am Soc Nephrol 2001; 12: 659–666.

  9. 9

    Nakaya H, Sasamura H, Kitamura Y, et al: Effects of angiotensin inhibitors on renal injury and angiotensin receptor expression in early hypertensive nephrosclerosis. Hypertens Res 1999; 22: 303–312.

  10. 10

    Ishiguro K, Sasanuma H, Sakamaki Y, Itoh H, Saruta T : Developmental activity of the renin-angiotensin system during the “critical period” modulates later L-NAME–induced hypertension and renal injury. Hypertens Res 2007; 30: 63–75.

  11. 11

    Airoldi F, Palatresi S, Marana I, et al: Angioplasty of atherosclerotic and fibromuscular renal artery stenosis: time course and predicting factors of the effects on renal function. Am J Hypertens 2000; 13: 1210–1217.

  12. 12

    Ramos F, Kotliar C, Alvarez D, et al: Renal function and outcome of PTRA and stenting for atherosclerotic renal artery stenosis. Kidney Int 2003; 63: 276–282.

Download references

Author information

Correspondence to Hideyasu Kiyomoto.

Rights and permissions

Reprints and Permissions

About this article

Keywords

  • angiotensin II receptor blockers (ARB)
  • TROPHY study
  • L-NAME
  • oxidative stress
  • nitric oxide